skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Non-Small Cell Lung Cancer mRNA-Derived Vaccine CV9201 (Code C84872)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Non-Small Cell Lung Cancer mRNA-Derived Vaccine CV9201

Definition: A non-small cell lung cancer (NSCLC) vaccine containing modified mRNAs encoding cancer-testis antigen NY-ESO-1, melanoma-associated antigens C1 (MAGE-C1/CT7) and C2 (MAGE-C2/CT10), survivin, and the oncofetal antigen 5T4 with potential antitumor and immunomodulatory activities. Upon subcutaneous administration, non-small cell lung cancer mRNA-derived vaccine CV9201 may stimulate the immune system to mount a cytotoxic, antigen-specific T lymphocyte response (CTL) against NSCLC cells. The modified mRNAs in this vaccine are taken up by cells after injection and exhibit enhanced translational potency. The five tumor-associated antigens (TAAs) encoded by these mRNAs are frequently expressed by NSCLC cells.

Label: Non-Small Cell Lung Cancer mRNA-Derived Vaccine CV9201

NCI Thesaurus Code: C84872 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL412376  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Non-Small Cell Lung Cancer mRNA-Derived Vaccine CV9201

External Source Codes: 
PDQ Closed Trial Search ID 648549
PDQ Open Trial Search ID 648549 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C84872
Semantic_Type Immunologic Factor
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom